Humacyte's Symvess Signs Contract with U.S. Department of Veterans Affairs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Humacyte announced that Symvess is now under contract with the with Strategic Acquisition Center of the U.S. Department of Veterans Affairs. The SAC contract makes Symvess more easily accessible to 170 VA hospitals as the SAC system is the preferred and primary sourcing vehicle for VA hospitals. "We are pleased that Symvess is now under contract with the Strategic Acquisition Center, making the first-in-class product accessible to healthcare professionals treating military veterans," said Dr. Laura Niklason, President and CEO of Humacyte, Inc. "SAC is the preferred sourcing vehicle for the VA, and we anticipate that the SAC SING contract will expedite our ability to respond to interest from surgeons operating in the VA system."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUMA
Wall Street analysts forecast HUMA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.280
Low
3.00
Averages
5.88
High
11.00
Current: 1.280
Low
3.00
Averages
5.88
High
11.00
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humacyte Reports Significant First Quarter Sales Growth
- Significant Sales Growth: Humacyte Inc reported first-quarter sales of SYMVESS reaching $0.5 million, a substantial increase from $0.1 million in 2025, indicating improved market acceptance, although the company acknowledges the need for faster sales growth to meet demand.
- International Market Expansion: The company has submitted a Marketing Authorization Application in Israel and secured a purchase commitment from Saudi Arabia, demonstrating progress in its international strategy, which is expected to drive future revenue growth.
- Increased R&D Spending: Research and development expenses rose to $19.5 million in the first quarter of 2026 from $15.4 million in 2025, reflecting ongoing investment in technological innovation despite the pressure on financial performance.
- Workforce Restructuring Impact: Humacyte implemented a 25% workforce reduction aimed at improving operational efficiency, but this may negatively affect employee morale and company culture, necessitating attention to its potential impact on future business execution.
See More
Humacyte Q1 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: Humacyte reported a Q1 GAAP EPS of -$0.09, beating expectations by $0.03, indicating the company's efforts in cost control, although overall financial performance still requires improvement.
- Revenue Decline: The company generated $0.5 million in revenue for the quarter, a 3.8% year-over-year decrease, missing market expectations by $0.96 million, reflecting challenges in market demand and sales strategies that could impact future cash flow.
- Product Rights Reacquisition: Humacyte regained ex-U.S. rights to Symvess from Fresenius Medical Care, signaling a strategic shift in global market expansion that may provide new revenue growth opportunities in the future.
- Industry Conference Participation: Humacyte presented at the Barclays 28th Annual Global Healthcare Conference, highlighting unmet needs and advancements in dialysis access, aiming to enhance the company's visibility and influence within the healthcare sector.
See More
Humacyte to Announce Q1 Earnings on May 13
- Earnings Announcement: Humacyte (HUMA) is set to release its Q1 2023 earnings report on May 13 before market open, with consensus EPS estimated at -$0.12 and revenue expected at $1.46 million, reflecting a significant year-over-year growth of 180.8%.
- Performance Expectations: Over the past year, HUMA has only beaten EPS estimates 25% of the time and has not exceeded revenue expectations, indicating challenges in achieving profitability.
- Estimate Revisions: In the last three months, EPS estimates have seen one upward revision and no downward adjustments, while revenue estimates have faced four downward revisions, suggesting a decline in market confidence regarding the company's future performance.
- Market Developments: Humacyte has regained ex-U.S. rights to Symvess from Fresenius Medical Care, potentially providing new opportunities for market expansion and product promotion in the future.
See More
Humacyte Realigns International Rights to Symvess Bioengineered Tissue
- International Rights Realignment: Humacyte has announced the realignment of international distribution rights for Symvess, securing exclusive distribution outside the U.S., which is expected to enhance revenue through low single-digit royalties on net sales and strengthen market competitiveness.
- FDA Approval Milestone: The biologics license application (BLA) for Humacyte's ATEV received FDA approval in December 2024, marking a significant milestone in the treatment of vascular trauma, which could drive future market demand and product applications.
- Advancement in Clinical Trials: The company is advancing preclinical trials for ATEV in coronary artery bypass grafts, pediatric heart surgery, and type 1 diabetes, showcasing its broad potential in multiple novel cell and tissue applications, which may open new revenue streams for the company.
- Market Performance: Humacyte's current trading price is $0.71, up 0.42%, reflecting positive market sentiment towards its new strategy and product advancements, potentially attracting more investor interest in its future growth.
See More
Humacyte Regains Exclusive Rights for Symvess Outside the U.S.
- Agreement Amendment: Humacyte (HUMA) amended its agreement with Fresenius Medical Care (FMS) on April 21, regaining exclusive rights to develop and commercialize Symvess outside the U.S., marking a strategic return to the global market.
- Product Background: Symvess received FDA approval in 2024 for extremity vascular trauma, and this move allows Humacyte to directly manage product development and regulatory matters in international markets.
- Financial Arrangement: Under the amended agreement, Humacyte will pay Fresenius low-single-digit royalties on overseas net sales after a two-year royalty-free period, supporting potential revenue growth for the company.
- Market Potential: The regained rights will enable Humacyte to respond more flexibly to international market demands, particularly in the Middle East, where it recently secured a $1.48 million purchase commitment for Symvess from Saudi Arabia, further enhancing its competitive position.
See More
Halper Sadeh LLC Investigates Humacyte Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages Humacyte shareholders to contact the firm to discuss their rights and options, emphasizing the importance of timely action to protect shareholder interests and seek legal remedies.
- Corporate Governance Reform: The investigation aims to determine whether Humacyte executives breached their fiduciary duties to shareholders, and if so, shareholders may seek governance reforms and fund recovery, thereby enhancing the company's transparency and accountability.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, which reduces the financial burden of participating in legal action and encourages more shareholders to engage.
- Investor Rights Advocacy: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
Humacyte Reports Significant First Quarter Sales Growth
- Significant Sales Growth: Humacyte Inc reported first-quarter sales of SYMVESS reaching $0.5 million, a substantial increase from $0.1 million in 2025, indicating improved market acceptance, although the company acknowledges the need for faster sales growth to meet demand.
- International Market Expansion: The company has submitted a Marketing Authorization Application in Israel and secured a purchase commitment from Saudi Arabia, demonstrating progress in its international strategy, which is expected to drive future revenue growth.
- Increased R&D Spending: Research and development expenses rose to $19.5 million in the first quarter of 2026 from $15.4 million in 2025, reflecting ongoing investment in technological innovation despite the pressure on financial performance.
- Workforce Restructuring Impact: Humacyte implemented a 25% workforce reduction aimed at improving operational efficiency, but this may negatively affect employee morale and company culture, necessitating attention to its potential impact on future business execution.
See More
Humacyte Q1 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: Humacyte reported a Q1 GAAP EPS of -$0.09, beating expectations by $0.03, indicating the company's efforts in cost control, although overall financial performance still requires improvement.
- Revenue Decline: The company generated $0.5 million in revenue for the quarter, a 3.8% year-over-year decrease, missing market expectations by $0.96 million, reflecting challenges in market demand and sales strategies that could impact future cash flow.
- Product Rights Reacquisition: Humacyte regained ex-U.S. rights to Symvess from Fresenius Medical Care, signaling a strategic shift in global market expansion that may provide new revenue growth opportunities in the future.
- Industry Conference Participation: Humacyte presented at the Barclays 28th Annual Global Healthcare Conference, highlighting unmet needs and advancements in dialysis access, aiming to enhance the company's visibility and influence within the healthcare sector.
See More
Humacyte to Announce Q1 Earnings on May 13
- Earnings Announcement: Humacyte (HUMA) is set to release its Q1 2023 earnings report on May 13 before market open, with consensus EPS estimated at -$0.12 and revenue expected at $1.46 million, reflecting a significant year-over-year growth of 180.8%.
- Performance Expectations: Over the past year, HUMA has only beaten EPS estimates 25% of the time and has not exceeded revenue expectations, indicating challenges in achieving profitability.
- Estimate Revisions: In the last three months, EPS estimates have seen one upward revision and no downward adjustments, while revenue estimates have faced four downward revisions, suggesting a decline in market confidence regarding the company's future performance.
- Market Developments: Humacyte has regained ex-U.S. rights to Symvess from Fresenius Medical Care, potentially providing new opportunities for market expansion and product promotion in the future.
See More
Humacyte Realigns International Rights to Symvess Bioengineered Tissue
- International Rights Realignment: Humacyte has announced the realignment of international distribution rights for Symvess, securing exclusive distribution outside the U.S., which is expected to enhance revenue through low single-digit royalties on net sales and strengthen market competitiveness.
- FDA Approval Milestone: The biologics license application (BLA) for Humacyte's ATEV received FDA approval in December 2024, marking a significant milestone in the treatment of vascular trauma, which could drive future market demand and product applications.
- Advancement in Clinical Trials: The company is advancing preclinical trials for ATEV in coronary artery bypass grafts, pediatric heart surgery, and type 1 diabetes, showcasing its broad potential in multiple novel cell and tissue applications, which may open new revenue streams for the company.
- Market Performance: Humacyte's current trading price is $0.71, up 0.42%, reflecting positive market sentiment towards its new strategy and product advancements, potentially attracting more investor interest in its future growth.
See More
Humacyte Regains Exclusive Rights for Symvess Outside the U.S.
- Agreement Amendment: Humacyte (HUMA) amended its agreement with Fresenius Medical Care (FMS) on April 21, regaining exclusive rights to develop and commercialize Symvess outside the U.S., marking a strategic return to the global market.
- Product Background: Symvess received FDA approval in 2024 for extremity vascular trauma, and this move allows Humacyte to directly manage product development and regulatory matters in international markets.
- Financial Arrangement: Under the amended agreement, Humacyte will pay Fresenius low-single-digit royalties on overseas net sales after a two-year royalty-free period, supporting potential revenue growth for the company.
- Market Potential: The regained rights will enable Humacyte to respond more flexibly to international market demands, particularly in the Middle East, where it recently secured a $1.48 million purchase commitment for Symvess from Saudi Arabia, further enhancing its competitive position.
See More
Halper Sadeh LLC Investigates Humacyte Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages Humacyte shareholders to contact the firm to discuss their rights and options, emphasizing the importance of timely action to protect shareholder interests and seek legal remedies.
- Corporate Governance Reform: The investigation aims to determine whether Humacyte executives breached their fiduciary duties to shareholders, and if so, shareholders may seek governance reforms and fund recovery, thereby enhancing the company's transparency and accountability.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, which reduces the financial burden of participating in legal action and encourages more shareholders to engage.
- Investor Rights Advocacy: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
